Panobinostat, gemcitabine, busulfan, and melphalan salvage therapy in RRMM
Here, we summarize a study published by Nieto et al. in American Journal of Hematology on the safety and efficacy of high-dose panobinostat combined with GemBuMel therapy following ASCT salvage in RRMM or high-risk MM.